However, promising drug targets are emerging such as COX-2,10,48 IL-1β, NLRP343,49 and CSF1R50,51 for tumour-associated macrophages and the PD-1/PDL1 axis for T-cells.20 By assessing and contrasting key components of the tumour microenvironment of sporadic and NF2-SWN VS, this study aimed to compare the broad immune landscape of these tumours. This evidence concerns the gene NF2 and neoplasm.